title: Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
abstract: BACKGROUND
  Palivizumab Outcomes Registry data collected during 4 years were examined to assess compliance and respiratory syncytial virus (RSV) hospitalization rates in high-risk children receiving palivizumab prophylaxis at home compared with an outpatient setting.
  
  
  METHODS
  Prospective observational registry enrolling high-risk infants who received > or = 1 dose of palivizumab throughout the 2000-2001 to 2003-2004 RSV seasons at participating U.S. pediatric sites.
  
  
  RESULTS
  Registry data were analyzed for compliance and RSV hospitalization outcomes in 19,548 infants receiving doses at home versus an outpatient setting. Compliance with the injection regimen was determined by comparing the number of palivizumab injections received versus the projected number of anticipated doses and by comparing infants receiving all injections within a 35-day interval. Compliance was significantly greater for infants who received palivizumab at home (n = 1226) as compared with those who received palivizumab in a clinic or office (n = 17,641), whether measured by the number of doses received (88% versus 81%, P < 0.0001) or by the timing of doses (73% versus 66%, P < 0.0001). Infants who received palivizumab at home also had fewer RSV-associated hospitalizations compared with those who received palivizumab in a clinic or office [0.4% (5/1226) versus 1.2% (207/17,641), P = 0.0139].
  
  
  CONCLUSIONS
  Home administration of palivizumab was associated with a significantly higher rate of compliance and lower hospitalization rate for RSV illness in high-risk infants.
authors.affiliation: Schneider Children's Hospital, New Hyde Park, NY 11042, USA. frogel@lij.edu
authors.forename: Michael
authors.initials: M
authors.lastname: Frogel
authors.forename: Cliff
authors.initials: C
authors.lastname: Nerwen
authors.forename: Marnie
authors.initials: M
authors.lastname: Boron
authors.forename: Alan
authors.initials: A
authors.lastname: Cohen
authors.forename: Paul
authors.initials: P
authors.lastname: VanVeldhuisen
authors.forename: Molly
authors.initials: M
authors.lastname: Harrington
authors.forename: Jessie
authors.initials: J
authors.lastname: Groothuis
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001990:Bronchiolitis, Viral / Q000188:drug therapy; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005865:Gestational Age; D006699:Home Care Services / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D000069455:Palivizumab; D010349:Patient Compliance / Q000706:statistics & numerical data*; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab